Last reviewed · How we verify
Polyglucosamine L112
At a glance
| Generic name | Polyglucosamine L112 |
|---|---|
| Also known as | Formoline L112 |
| Sponsor | Certmedica International GmbH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects (PHASE4)
- Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption (NA)
- Polyglucosamine L112 in Overweight and Obese Subjects (NA)
- Efficacy of Polyglucosamine Long Term Treatment (NA)
- Efficacy of Polyglucosamine for Weight Loss (NA)
- RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polyglucosamine L112 CI brief — competitive landscape report
- Polyglucosamine L112 updates RSS · CI watch RSS
- Certmedica International GmbH portfolio CI